Orthofix Med Inc SEC Filings

Orthofix Medical (NASDAQ:OFIX) filed a Form 4 disclosing that director Vickie L. Capps was granted 18,841 deferred stock units on 18 June 2025. These units vest in full one year after the grant date, contingent upon continued board service, and will convert into common shares within 45 days of her separation from the company. Following the award, Capps’ reported beneficial ownership increased to 21,934 shares, which includes 3,093 previously disclosed units. The award carries no purchase price and no insider sales were reported.

Orthofix Medical (NASDAQ: OFIX) filed a routine Form 4 disclosing that director Wayne Burris was granted 18,841 deferred stock units (DSUs) on 06/18/2025 at no cost as part of board compensation. The award vests in full one year after the grant date, provided continued service, and will convert to common stock within 45 days after the director leaves the board.

Following the grant, Burris’ total beneficial ownership increased to 50,539 shares, which includes 25,315 previously reported DSUs. The filing reports no share sales, cash proceeds, or changes to Orthofix’s operations or financial outlook.

Orthofix Medical (NASDAQ:OFIX) submitted a routine Form 4 disclosing that director Alan Lee Bazaar received 18,841 deferred stock units on 06/18/2025 as part of standard board compensation.

The units vest in full on the first anniversary of the grant date, contingent upon continued service, and convert into common stock within 45 days of the director’s termination of service. The transaction price is recorded as $0, indicating a non-cash equity award. After the grant, Bazaar beneficially owns 49,824 shares, which include 24,088 previously reported deferred stock units. No shares were sold or disposed of, and the filing notes no other material changes.

Orthofix Medical (OFIX) filed a Form 4 disclosing that director Charles R. Kummeth was granted 18,841 deferred stock units (DSUs) on 06/18/2025 at no cost. The DSUs vest in full on the first anniversary of the grant date and will convert into common stock within 45 days after his service with the company ends. Following the award, Kummeth’s total beneficial ownership rose to 59,237 shares, which now includes 23,502 previously reported DSUs and 1,894 shares accumulated through Orthofix’s Stock Purchase Plan.

Royal Bank of Canada (RY) is marketing senior unsecured Digital EURO STOXX 50® Index-Linked Notes under a 424B2 filing. The notes pay no periodic interest and have an expected tenor of 24-27 months. Repayment is tied to the EURO STOXX 50 (SX5E):

• If the final index level is at least 85% of the initial level, investors receive a fixed Threshold Settlement Amount of approximately $1,151.30–$1,178.00 per $1,000 note (a 15.13%–17.8% upside).
• If the index finishes below the 85% threshold, principal is reduced by an accelerated factor—$1,000 + 1.1765 × (index return + 15%). Losses can reach 100% of principal.

The initial estimated value is $963.70–$993.70, below par, indicating embedded fees and market factors. Underwriting discount is 0%, so RBC receives 100% of proceeds. Minimum denomination is $1,000; transfers in $1,000 increments.

Key risks highlighted include: potential full loss of principal, exposure to RBC credit risk, market value below issue price before maturity, and lack of CDIC/FDIC insurance or bail-in conversion protection. Detailed terms and risk factors are provided in the accompanying prospectus, prospectus supplement, underlying supplement 1A and product supplement 1A.

On June 30, 2025, MediaAlpha, Inc. (NYSE: MAX) filed a Form 8-K announcing technology-leadership changes and related compensation matters.

Item 5.02 – Executive transition. Chief Technology Officer Eugene Nonko resigned effective June 30, 2025, and simultaneously entered into a Fifth Amendment to his employment agreement to remain as Chief Architect, a non-executive individual-contributor role.

• Base salary: unchanged at $550,000 for 2025.
• Cash incentive bonus: 100 % of salary for 1H25 and 70 % for 2H25, delivering a blended 85 % target, or $467,500, subject to the same corporate metrics used for other senior executives.
• Equity awards: (1) Previously granted RSUs with a $2.75 million grant-date value (50 % of his $5.5 million CTO target opportunity); (2) an additional RSU award valued at $750,000 will be granted 15 July 2025, calculated by dividing $750,000 by the 20-day average share price. All RSUs vest in 16 equal quarterly instalments beginning 15 Aug 2025, contingent upon continued service.

The amendment is filed as Exhibit 10.1.

Item 7.01 – Regulation FD. The company furnished a press release (Exhibit 99.1) announcing the appointment of Amy Yeh as the new Chief Technology Officer. The information under Item 7.01 is considered “furnished,” not “filed,” under the Exchange Act.

Orthofix Medical Inc. (OFIX) – Form 4 insider filing dated 06/23/2025

Director John B. Henneman III reported a single equity-compensation transaction that occurred on 06/18/2025.

• Securities granted: 18,841 deferred stock units (DSUs) coded “A” (award).
• Price: $0, confirming the grant was part of the company’s director compensation plan rather than an open-market purchase or sale.
• Vesting schedule: DSUs vest 100 % on the first anniversary of the grant provided the director continues in service. Each DSU converts into one share of common stock within 45 days after the director’s service ends.
• Post-transaction beneficial ownership: 83,706 OFIX common shares, comprising the newly granted 18,841 DSUs, 29,506 previously reported DSUs, and 951 shares acquired under the Orthofix Stock Purchase Plan on 04/30/2025.
• The filing was executed by attorney-in-fact J. Andres Cedron and submitted on 06/23/2025.

No derivative securities were reported in Table II, and the filing indicates a single reporting person with director status. The form contains no indication of a 10b5-1 trading plan and no amendments to earlier filings.

Orthofix Medical Inc. (OFIX) – Form 4 insider transaction

On 18 June 2025, Aviva McPherron, President of Global Operations & Quality at Orthofix Medical, reported the sale of 3,728 common shares at $10.51 per share (approx. $39.2 thousand total). The Form 4 states the sale was executed under a mandatory, pre-approved sell-to-cover instruction to satisfy tax-withholding obligations arising from the settlement of restricted stock units (RSUs). The reporting person had no discretion over the timing or pricing of the trade.

Following the transaction, McPherron continues to beneficially own 46,322 shares, which includes 37,557 previously reported RSUs. No derivative security activity was disclosed, and there were no other open-market or discretionary sales.

The filing signals a routine, administrative share sale rather than a strategic divestment, leaving the officer with a substantial equity interest aligned with shareholders.